Tysabri News
Most Popular Tysabri Story
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the... Read more...
Latest Headlines
- April 22, 2009
- March 26, 2009
- February 6, 2009
- August 1, 2008
- January 29, 2008
- January 10, 2008
- December 13, 2007
- November 14, 2007
- November 8, 2007
- October 15, 2007
- October 12, 2007
- August 22, 2007
- August 1, 2007
- July 23, 2007
- December 18, 2006
- October 31, 2006
- October 23, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
